Please try another search
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. The company also offers Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. The company was incorporated in 2011 and is based in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Yi Zhang | 49 | 2018 | Senior VP of Pharma Development, Chief Medical Officer – China and Executive Director |
Li Chen | 61 | 2010 | Founder, CEO & Executive Director |
William Robert Keller | 76 | 2018 | Independent Non-Executive Director |
Catherine D. Strader | 69 | - | Member of Scientific Advisory Board |
Bennett M. Shapiro | 84 | - | Member of Scientific Advisory Board |
Yiu Wa Tsui | 74 | 2018 | Independent Non-Executive Director |
Robert Taylor Nelsen | 62 | 2010 | Non-Executive Chairman |
Fangxin Li | 31 | 2023 | Non-Executive Director |
James S. MacDonald | - | - | Member of Scientific Advisory Board |
Chien Cheng Lin | 53 | 2017 | Executive VP, Chief Strategy Officer & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review